Literature DB >> 10579970

Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.

P H Rubin1, S Friedman, N Harpaz, E Goldstein, J Weiser, J Schiller, J D Waye, D H Present.   

Abstract

BACKGROUND & AIMS: Adenomatous polyps are by definition dysplastic and pathologically indistinguishable from the dysplasia-associated lesion or mass (DALM) described in 1981. Yet, adenomatous polyps in noncolitic colons are usually removed definitively endoscopically, whereas DALMs are regarded as harbingers of colon cancer, mandating colectomy.
METHODS: Since 1988, all of our patients with chronic ulcerative or Crohn's colitis and dysplastic polyps and no coexistent dysplasia in flat mucosa underwent colonoscopic polypectomy. Biopsy specimens were obtained also adjacent to polypectomy sites, from strictures, and throughout the colon at 10-cm intervals. Follow-up colonoscopies and biopsies were performed within 6 months after polypectomy and yearly thereafter.
RESULTS: Colonoscopy in 48 patients with chronic colitis (mean duration, 25.4 years) resected 70 polyps (60 in colitic and 10 in noncolitic mucosa). Polyps were detected on screening colonoscopies (29%) and on surveillance (71%). Pathology was tubular adenoma in all polyps from noncolitic mucosa and low-grade dysplasia (57), high-grade dysplasia (2), or carcinoma (1) in polyps from colitic mucosa. Subsequent colonoscopies (mean follow-up, 4.1 years) revealed additional polyps in 48% but no carcinomas. Surgical resection (6 patients) for recurrent polyps confirmed colonoscopic findings. No dysplasia or cancers in flat mucosa were found at surgery or on follow-up colonoscopies.
CONCLUSIONS: In patients with chronic colitis who have no dysplasia in flat mucosa, colonoscopic resection of dysplastic polyps can be performed effectively, just as in noncolitic colons.

Entities:  

Mesh:

Year:  1999        PMID: 10579970     DOI: 10.1016/s0016-5085(99)70279-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  58 in total

Review 1.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

2.  Endoscopic Therapy for Inflammatory Bowel Disease.

Authors:  Eric S. Goldstein; Peter H. Rubin
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

3.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

4.  Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership.

Authors:  David T Rubin; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

Review 5.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

Review 6.  Dysplasia and colitis.

Authors:  Robert Enns; Brian Bressler
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

Review 7.  Colonic crohn disease.

Authors:  Traci L Hedrick; Charles M Friel
Journal:  Clin Colon Rectal Surg       Date:  2013-06

8.  Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer.

Authors:  Sabine Tejpar; Robert D Odze
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 9.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

Review 10.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.